Point of Care Diagnostics Market Size is valued at USD 15.59 Billion in 2024 and is predicted to reach USD 34.68 Billion by the year 2034 at a 8.4% CAGR during the forecast period for 2025-2034.
Point-Of-Care diagnostic devices are used for early and quick diagnosis of diseases. These techniques are highly sensitive, cost-effective, and produce immediate results. Point-of-care diagnostics have many advantages in the physician’s office, home healthcare, research laboratory, and in the hospital. One of the major factors responsible for the growth of this market are the rising prevalence of chronic and infectious diseases all over the world. Moreover, the COVID-19 pandemic has significantly affected the point of care diagnostics market. An increasing number of COVID-19 patients forcing the healthcare industry to develop rapid and advance testing tools, driving the opportunities for POC market.
High prevalence of infectious diseases, rising human health issues, need for rapid diagnostics, lack of advanced technologies in the diagnostic labs, growing preference for home healthcare, new inventions and innovations by key players, changes in lifestyle patterns, and increasing healthcare expenditure will create more opportunities to expand the point of care diagnostics market during the forecast period.
The point of care diagnostics market can be segmented on the basis of products, Platform, mode of purchase, technology, sample type, end-users, and region. Firstly, the Product segment consists of Glucose Monitoring Products (Strips, Meters, Lancets & Lancing Devices), Cardiometabolic Monitoring Products (Cardiac Marker Testing, Blood Gas/Electrolyte Testing, HbA1c Testing), Infectious Disease Testing Products (Respiratory Infection Testing [Influenza, Tuberculosis, Others], Healthcare-Associated Infection Testing, Tropical Disease Testing, Sexually Transmitted Disease Testing [HIV, Hepatitis, Syphilis, HPV, Chlamydia, Gonorrhea, Herpes], Clostridium difficile Infection Testing, Other Infectious Disease Testing), Coagulation Monitoring Products (PT/INR, ACT/APTT), Pregnancy & Fertility Testing Products (Pregnancy, Fertility), Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Thyroid-Stimulating Hormone Testing Products, Fecal Occult Testing Products, Other Products). According to the Mode of Purchase, the market is further divided into Prescription-Based Testing Products, OTC Testing Products. Whereas, By Technology, the overall market is again subdivided into Biochemistry, Immunoassays, Molecular Diagnostics (RT-PCR, INAAT). The Sample Type segment comprises Blood Samples, Nasal & Oropharyngeal Swabs, Urine Samples, Other Samples. Whereas, the End User segment includes Home Care Settings & Self-Testing, Clinical Laboratories, Hospitals/Critical Care/Urgent Care Centers, Ambulatory Care Facilities & Physician Offices, and Other End Users.
The glucose monitoring category constitutes the largest portion of the point-of-care diagnostics market, primarily due to the rising prevalence of diabetes globally. The global prevalence of diabetes among millions of patients underscores the necessity for continuous glucose monitoring via regular blood glucose assessments, hence supporting the demand for reliable, accurate, and user-friendly glucose testing instruments. The improvement of technology, precision, user-friendliness, and cost are pivotal elements that enhance the adoption rates of glucose monitoring systems by both patients and healthcare practitioners.
In 2024, biochemistry constituted the predominant segment of the point-of-care diagnostics market. Biochemical markers, including glucose, electrolytes, and lipids, must be assessed for chronic disorders such as kidney diseases, diabetes, and cardiovascular disease, which create substantial demand for biochemistry technology. Biochemistry-based point-of-care devices are favored for their simplicity, rapidity, and cost-efficiency in clinical and home-care environments. Furthermore, smaller analyzers enhanced the accuracy and utility of the items, hence augmenting their demand.
In 2024, North America led the market because to its robust healthcare infrastructure and accessibility to advanced diagnostic technology. Lifestyle diseases, such diabetes, are prevalent and have therefore heightened the demand for immediate, point-of-care testing options. The region benefits from robust government programs for research and product innovation, as well as regulatory clearances for the development of innovative point-of-care diagnostic technologies with extensive uptake.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 15.59 Billion |
| Revenue Forecast In 2034 | USD 34.68 Billion |
| Growth Rate CAGR | CAGR of 8.4% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Mode of purchase, Technology, Sample type, By End-Users |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Abbott Laboratories, Nova Biomedical, Chembio Diagnostic Systems, Inc., Danaher Corporation, Ekf Diagnostics Holdings Plc, Werfenlife, S.A., Johnson & Johnson Services, Inc., Hoffmann-La Roche Ltd., Sekisui Chemical Co. Ltd., Dickinson, And Company (Bd), Quidel Corporation, Siemens Ag, Trinity Biotech, Accubiotech Co., Ltd., and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Point of Care Diagnostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Products
Global Point of Care Diagnostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Mode of Purchase
Global Point of Care Diagnostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Technology
Global Point of Care Diagnostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Sample Type
Global Point of Care Diagnostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on End-users
Global Point of Care Diagnostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Region
North America Point of Care Diagnostics Market Revenue (US$ Billion) by Country
Europe Point of Care Diagnostics Market Revenue (US$ Billion) by Country
Asia Pacific Point of Care Diagnostics Market Revenue (US$ Billion) by Country
Latin America Point of Care Diagnostics Market Revenue (US$ Billion) by Country
Middle East & Africa Point of Care Diagnostics Market Revenue (US$ Billion) by Country
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.